Clinical Trial of High Dose Lisdexamfetamine and Contingency Management in MA Users
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-55
SponsorCentre hospitalier de l'Université de Montréal (CHUM)
About this trial
The goal of this clinical trial is to learn if administering a high dose stimulant with Contingency Management reduces days of use in adults who use methamphetamine better than the usual treatment provided by the clinic.
The main questions the trial aims to answer are:
Is a high dose stimulant better than a placebo and usual treatment at helping reduce the number of days they use methamphetamine? Is a high dose stimulant with contingency management better than placebo and usual treatment at helping people reduce the number of days they use methamphetamine?
Participants will be placed randomly into one of four groups:
1. Usual treatment and placebo 2. Usual treatment, placebo and contingency management 3. Usual treatment and high dose stimulant 4. Usual treatment, high dose stimulant and contingency management
Participation includes the following:
1. Participants will receive medication or placebo weekly for 15 weeks. 2. Participants will attend the clinic for weekly treatment 3. Participants will attend the clinic once every 2 weeks for study visits. Each visit will take about an hour to complete. At these visits, participants will be asked to provide a urine sample and complete questionnaires.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Between 18 and 55 years of age;
Diagnosed with a moderate to severe methamphetamine (MA) use disorder as defined by the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, 5th edition) criteria;
Active MA use at screening measured via self-reported MA use ≥14 days in the past 28 days AND verified by urine drug metabolite testing;
Interested in reducing/stopping MA use;
Disqualifiers
1. Symptomatic or advanced cardiovascular disease (e.g., advanced arteriosclerosis), moderate hypertension; current hyperthyroidism confirmed via blood test; known hypersensitivity or idiosyncrasy to the sympathomimetic amines or glaucoma or any disabling, severe, OR unstable medical condition that, in the opinion of the study physician, precludes safe participation or the ability to provide fully informed consent; 2. Any severe or unstable co-morbid substance use disorder that, in the opinion of the study physician, precludes safe participation in the study; 3. Participants with Opioid Use Disorder (OUD) who have been on Opioid Agonist Therapy (OAT) for < 12 weeks, and not yet at stabilization dose, or at stabilization dose < 4 weeks; 4. Current or history of any serious psychiatric disorder (e.g., bipolar disorder, pre-existing psychosis, schizophrenia) that, in the opinion of the study physician, precludes safe participation in the study; 5. History of a severe adverse event, hypersensitivity or known allergic reaction to LDX or other amphetamine drugs OR hypersensitivity to the sympathomimetic amines; 6. Pregnant, nursing, or planning to become pregnant during the study period; 7. Planned extended absence during study period (e.g., pending legal action, surgery, incarceration, inpatient residential program) in the opinion of the study physician that might prevent completion of the study; 8. Use of an investigational drug for stimulant use disorder during the 30 days prior to screening, confirmed via self-report OR pharmacy records; 9. Currently receiving contingency management for the treatment of stimulant use disorder in the 4 weeks prior to screening, confirmed via self-report OR site records; 10. Use of prescribed amphetamine-type medication OR medication for the treatment of stimulant use disorder (e.g., methylphenidate, modafinil, bupropion) in the 4 weeks prior to screening; 11. Current or anticipated need for treatment with any medication that may interact with LDX (e.g., proton pump inhibitors, monoamine oxidase inhibitors [MAOIs]) used currently or within the past 14 days AND that would preclude study participant at the discretion of the study physician
Trial design
Design model
Parallel
Treatments tested in this trial
Treatment as Usual plus Placebo
DrugParticipants receive once daily Lisdexamfetamine matched placebo for 15 weeks, as well as treatment as usual at clinical site.
Treatment as Usual plus Placebo plus Contingency Management
DrugParticipants receive once daily Lisdexamfetamine matched placebo for 15 weeks, as well as treatment as usual at clinical site, and engagement-focused contingency management for 12 weeks, week 2-13.
Treatment as Usual plus lisdexamfetamine (LDX-01)
DrugParticipants receive once daily Lisdexamfetamine for 15 weeks, as well as treatment as usual at clinical site. Medication is provided in 3 phases: Week 1 (Induction Phase): 100 mg (Day 1 and 2), 150 mg (Day 3 and 4), 200 mg (Day 5, 6 and 7) Weeks 2-13 (Maintenance Phase): 250 mg per day (or the maximum tolerated for each individual) and then will continue on the same daily dose Weeks 14-15 (Taper Phase): 150 mg (Week 14) and 50 mg (Week 15).
Treatment as Usual plus lisdexamfetamine (LDX-01) plus Contingency Management
DrugParticipants receive once daily Lisdexamfetamine for 15 weeks, as well as treatment as usual at clinical site. Medication is provided in 3 phases: Week 1 (Induction Phase): 100 mg (Day 1 and 2), 150 mg (Day 3 and 4), 200 mg (Day 5, 6 and 7) Weeks 2-13 (Maintenance Phase): 250 mg per day (or the maximum tolerated for each individual) and then will continue on the same daily dose Weeks 14-15 (Taper Phase): 150 mg (Week 14) and 50 mg (Week 15). Engagement-focused contingency management will be provided for 12 weeks, Week 2-13.
Treatment groups
440 Participants
are divided into 4 treatment groupsGroup A: Treatment as Usual plus PlaceboPlacebo comparator 1 intervention
Group B: Treatment as Usual plus Placebo plus Contingency ManagementPlacebo comparator 1 intervention
Group C: Treatment as Usual plus lisdexamfetamine (LDX-01)Active comparator 1 intervention
Group D: Treatment as Usual plus lisdexamfetamine (LDX-01) plus Contingency ManagementActive comparator 1 intervention
Trial outcomes
Primary outcomes
1
Total number of days of methamphetamine use during maintenance phase
The primary outcome measure is the total number of days of MA use during the 12-week maintenance treatment period of the trial, assessed via self-report using the Timeline Followback (TLFB) Questionnaire.
Time frame
12 weeksSecondary outcomes
1
Medication Adherence
Medication adherence will be measured by the number of days the medication is taken as prescribed. The medication is provided to the patient in Blister Packaging, with an electronic data monitoring system affixed. The date and time each dose is taken by participant will be recorded by the electronic blister pack database. This data will be extracted from an Electronic Blister Packaging Database, and pharmacy abstraction. Retention on study medication/placebo will be defined as the proportion of participants (LDX-01 or placebo) at D1 of Week 15, having an active prescription for the treatment, confirmation via self-report by the participant of ingestion of medication/placebo and monitoring of the electronic blister pack.
Time frame
15 weeks2
Safety Events
Safety in the trial will be evaluated by monitoring adverse events and serious adverse events over the entire course of the study; (i.e., baseline (Day 1), Day 3, and Day 5 of Week 1, and Day 1 of Weeks 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, and 20 (end of follow-up). Adverse events and serious adverse events will be defined and documented according to the adverse reporting procedures.Information regarding safety events will be collected via self-report, report from others, or chart abstraction, or all of the above.
Time frame
20 weeks3
Changes in Quality of Life
Quality of life will be measured using the WHO Quality of Life-BREF40 which is person-centred generic patient-reported quality of life measure, being validated to document and follow changes in quality of life in different physical and psychiatric disorders. It specifically looks at 4 domains related to quality of life: physical health, psychological health, social relationships, and environment. Quality of Life Assessment will yield data on the number of participants that report more positive quality of life in the domains of physical health, psychological health, social relationships, and environment.
Time frame
Will be administered at Baseline, Week 8, 14 and 20.4
Methamphetamine and other Substance Use - self report
Methamphetamine and other substance use will be measured every two weeks by self report using the time line follow back (TLFB). The TLFB collects self-reported substance use amount, frequency, and duration retrospectively over the past 14 days. The TLFB has shown very good reported psychometric properties in adults using substances.
Time frame
15 weeksSponsors and contacts
Click on the lead sponsor to view all of their trials.
Centre hospitalier de l'Université de Montréal (CHUM)
Lead sponsor
Canadian Institutes of Health Research (CIHR)
Collaborator
Source ClinicalTrials.gov